MIST Milestone Pharmaceuticals
- 1.690
- +0.050+3.05%
- 1.690
- 0.0000.00%
Milestone Pharmaceuticals News
Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation
Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present d
Express News | Milestone Pharmaceuticals Disclosed Resubmission Of New Drug Application For Etripamil For Treatment In Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova
Analysts' Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Milestone Pharmaceuticals' Etripamil Nears Approval: A Strong Buy Recommendation
Milestone Pharmaceuticals: Q4 Earnings Insights
Milestone Pharmaceuticals (NASDAQ:MIST) reported its Q4 earnings results on Thursday, March 21, 2024 at 07:14 AM.Here's what investors need to know about the announcement.EarningsMilestone Pharmaceuti
Milestone Pharmaceuticals Q4 GAAP EPS $(0.32) Misses $(0.31) Estimate; Cash Balance Of $66M Expected To Provide Cash Runway Into 2026
aMilestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 3.23 percent decrease over los
Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Re
Milestone Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Milestone Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $5
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals with a Overweight and lowers the price target from $6 to $5.
Milestone Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 233.33% Piper Sandler $6 → $5 Maintains Overweight 02/26/2024 1566.67% HC Wainwright & Co. → $2
Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that members of its management team will participate in a corporate panel discussion at
Milestone Pharmaceuticals Shares Fall Premarket After Stock Offering
By Colin Kellaher Shares of Milestone Pharmaceuticals slid more than 20% in premarket trading after the biopharmaceutical company said it was raising $30 million in a dilutive public offering. The M
Express News | Milestone Pharmaceuticals Priced Its Public Offering Of 16.7M Shares At $1.50/Share And Pre-funded Warrants To Purchase 3.3M Shares At $1.49/Pre-funded Warrant, With Gross Proceeds Of Approximately $30M
Milestone Pharma Shares Drop After Public Offering News
By Stephen Nakrosis Shares of Milestone Pharmaceuticals were down in after-hours trading following news the company commenced an underwritten public offering of its common shares and warrants. After
Milestone Pharmaceuticals Announces Proposed Public Offering Of Common Shares And Pre-Funded Warrants
Milestone Pharmaceuticals Announces Proposed Public Offering Of Common Shares And Pre-Funded Warrants
Analysis
Price Target
No Data
